Marwan Noel Sabbagh
#140,816
Most Influential Person Now
Marwan Noel Sabbagh's AcademicInfluence.com Rankings
Marwan Noel Sabbaghphilosophy Degrees
Philosophy
#7343
World Rank
#10543
Historical Rank
Logic
#4402
World Rank
#5687
Historical Rank
Marwan Noel Sabbaghbiology Degrees
Biology
#9970
World Rank
#13243
Historical Rank
Neuroscience
#1501
World Rank
#1552
Historical Rank
Download Badge
Philosophy Biology
Marwan Noel Sabbagh's Degrees
- Doctorate Medicine University of Arizona
- PhD Neuroscience University of Arizona
Why Is Marwan Noel Sabbagh Influential?
(Suggest an Edit or Addition)Marwan Noel Sabbagh's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. (2014) (1543)
- Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins (2007) (1037)
- Use of florbetapir-PET for imaging beta-amyloid pathology. (2011) (938)
- Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders (2010) (739)
- Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis (2016) (716)
- Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study (2012) (652)
- Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction (2009) (510)
- Alzheimer's disease drug development pipeline: 2019 (2019) (491)
- Amyloid β peptide load is correlated with increased β-secretase activity in sporadic Alzheimer's disease patients (2004) (457)
- Defining mild cognitive impairment in Parkinson's disease (2007) (424)
- Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. (2009) (417)
- Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. (2005) (403)
- Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study (2015) (374)
- Low clinical diagnostic accuracy of early vs advanced Parkinson disease (2014) (363)
- New Acetylcholinesterase Inhibitors for Alzheimer's Disease (2011) (335)
- A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease (2009) (327)
- Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease (2009) (308)
- Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. (2013) (307)
- Profiles of Extracellular miRNA in Cerebrospinal Fluid and Serum from Patients with Alzheimer's and Parkinson's Diseases Correlate with Disease Status and Features of Pathology (2014) (303)
- Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program (2015) (265)
- Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. (2015) (238)
- The Sun Health Research Institute Brain Donation Program: Description and Eexperience, 1987–2007 (2007) (234)
- The Montreal Cognitive Assessment and the Mini-Mental State Examination as Screening Instruments for Cognitive Impairment: Item Analyses and Threshold Scores (2011) (226)
- Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease. (2016) (224)
- Circle of Willis atherosclerosis: association with Alzheimer’s disease, neuritic plaques and neurofibrillary tangles (2006) (222)
- The Impact of Mild Cognitive Impairment on Gait and Balance: A Systematic Review and Meta-Analysis of Studies Using Instrumented Assessment (2016) (216)
- A Phase II Study of Fornix Deep Brain Stimulation in Mild Alzheimer’s Disease (2016) (210)
- Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group (2021) (204)
- A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease (2007) (204)
- Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer's pathology (2016) (201)
- Four distinct trajectories of tau deposition identified in Alzheimer’s disease (2021) (200)
- Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline (2012) (198)
- Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging (2013) (197)
- The influence of diet (2011) (181)
- Pathologic findings in prospectively ascertained essential tremor subjects (2008) (179)
- Use of Florbetapir-PET for Imaging-Amyloid Pathology (2011) (172)
- Olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body disorders (2008) (162)
- Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE (2015) (161)
- Parkinson Disease With Dementia: Comparing Patients With and Without Alzheimer Pathology (2009) (160)
- Cerebral blood flow in Alzheimer’s disease (2012) (157)
- Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment. (2006) (151)
- Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval (2020) (148)
- A position paper (2007) (145)
- Morphological and Pathological Evolution of the Brain Microcirculation in Aging and Alzheimer’s Disease (2012) (144)
- Drug development for Alzheimer's disease: where are we now and where are we headed? (2009) (144)
- Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease (2014) (142)
- Predicting Alzheimer’s disease progression using multi-modal deep learning approach (2019) (136)
- PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease (2011) (134)
- Statin therapy in Alzheimer's disease (2006) (132)
- The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis (2019) (131)
- Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals (2013) (124)
- Reduced risk of incident AD with elective statin use in a clinical trial cohort. (2008) (120)
- Alzheimer's disease drug development pipeline: 2020 (2020) (118)
- REM sleep behavior disorder and neuropathology in Parkinson's disease (2015) (117)
- Frequency of Alzheimer’s disease pathology at autopsy in patients with clinical normal pressure hydrocephalus (2011) (116)
- Aducanumab produced a clinically meaningful benefit in association with amyloid lowering (2021) (114)
- Both early and late cognitive dysfunction affects the electroencephalogram in Parkinson's disease. (2007) (112)
- Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains (2013) (111)
- Reduced striatal tyrosine hydroxylase in incidental Lewy body disease (2008) (107)
- Hippocampal Sclerosis Contributes to Dementia in the Elderly (1997) (105)
- Transcranial Doppler ultrasound blood flow velocity and pulsatility index as systemic indicators for Alzheimer’s disease (2011) (105)
- Hexanucleotide repeat expansions in C9ORF72 in the spectrum of motor neuron diseases (2012) (104)
- FDA position statement “Early Alzheimer's disease: Developing drugs for treatment, Guidance for Industry” (2019) (103)
- Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinson's disease subjects (2014) (102)
- Incidental Lewy body disease: Clinical comparison to a control cohort (2010) (99)
- Sensitivity to change and prediction of global change for the Alzheimer’s Questionnaire (2015) (99)
- Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimer's disease (2014) (97)
- Hippocampal adaptation to face repetition in healthy elderly and mild cognitive impairment (2004) (97)
- Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease (2020) (96)
- Submandibular gland biopsy for the diagnosis of Parkinson disease. (2013) (95)
- Effect of TTP488 in patients with mild to moderate Alzheimer’s disease (2014) (90)
- Intracranial atherosclerosis as a contributing factor to Alzheimer’s disease dementia (2009) (88)
- HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier. (2002) (87)
- Amyloid load in nondemented brains correlates with APOE e4 (2010) (85)
- Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study (2018) (83)
- Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts (2017) (82)
- Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer’s disease (2011) (81)
- Relationship of cognitive measures and gray and white matter in Alzheimer's disease. (2006) (80)
- Hippocampal Sclerosis Dementia with Tauopathy (2003) (77)
- Heterogeneous neuropathological findings in Parkinson’s disease with mild cognitive impairment (2010) (75)
- Marked microglial reaction in normal aging human substantia nigra: correlation with extraneuronal neuromelanin pigment deposits (2007) (75)
- Non-coding variability at the APOE locus contributes to the Alzheimer’s risk (2019) (74)
- Impact of Training Method on the Robustness of the Visual Assessment of 18F-Florbetaben PET Scans: Results from a Phase-3 Study (2016) (73)
- Diagnosis of Early Alzheimer’s Disease: Clinical Practice in 2021 (2021) (71)
- Functional, global and cognitive decline correlates to accumulation of Alzheimer's pathology in MCI and AD. (2010) (71)
- Development of Azeliragon, an Oral Small Molecule Antagonist of the Receptor for Advanced Glycation Endproducts, for the Potential Slowing of Loss of Cognition in Mild Alzheimer’s Disease (2018) (70)
- Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD. (2005) (69)
- Robust Identification of Alzheimer’s Disease subtypes based on cortical atrophy patterns (2017) (69)
- Alzheimer's Disease and Non-Demented High Pathology Control Nonagenarians: Comparing and Contrasting the Biochemistry of Cognitively Successful Aging (2011) (69)
- Probable RBD is increased in Parkinson's disease but not in essential tremor or restless legs syndrome. (2011) (68)
- No evidence for cognitive dysfunction or depression in patients with mild restless legs syndrome (2009) (68)
- Graph theory network function in Parkinson’s disease assessed with electroencephalography (2016) (67)
- Administration and scoring variance on the ADAS-Cog. (2008) (66)
- Olfactory dysfunction in incidental Lewy body disease and Parkinson's disease. (2014) (64)
- Gender Differences in Alzheimer Disease: Brain Atrophy, Histopathology Burden, and Cognition (2016) (64)
- Striatal amyloid plaque density predicts Braak neurofibrillary stage and clinicopathological Alzheimer's disease: implications for amyloid imaging. (2012) (63)
- Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson’s disease subjects (2012) (63)
- Longitudinal EEG changes correlate with cognitive measure deterioration in Parkinson's disease. (2015) (62)
- Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology (2011) (62)
- Alzheimer disease without neocortical neurofibrillary tangles (2004) (62)
- Deep Brain Stimulation Targeting the Fornix for Mild Alzheimer Dementia (the ADvance Trial): A Two Year Follow-up Including Results of Delayed Activation. (2018) (61)
- Salivary beta amyloid protein levels are detectable and differentiate patients with Alzheimer’s disease dementia from normal controls: preliminary findings (2018) (61)
- Use of Flutemetamol F 18–Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment (2018) (61)
- Biochemical Increase in Phosphorylated Alpha‐Synuclein Precedes Histopathology of Lewy‐Type Synucleinopathies (2012) (61)
- Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging. (2006) (61)
- Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer’s disease (2015) (59)
- Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer's dementia (2015) (59)
- Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans (2012) (59)
- Effects of a combined transcranial magnetic stimulation (TMS) and cognitive training intervention in patients with Alzheimer's disease (2019) (59)
- Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease (2017) (59)
- Clinicopathological outcomes of prospectively followed normal elderly brain bank volunteers. (2014) (59)
- Interaction of cardiovascular disease and neurodegeneration: transcranial Doppler ultrasonography and Alzheimer's disease (2006) (59)
- The nicotinic acetylcholine receptor, smoking, and Alzheimer's disease. (2002) (58)
- Longitudinal measurement and hierarchical classification framework for the prediction of Alzheimer’s disease (2017) (58)
- No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data (2017) (57)
- Is there a characteristic lipid profile in Alzheimer's disease? (2005) (57)
- Challenges and Opportunities with Causal Discovery Algorithms: Application to Alzheimer’s Pathophysiology (2020) (56)
- High‐Dose Donepezil (23 mg/day) for the Treatment of Moderate and Severe Alzheimer's Disease: Drug Profile and Clinical Guidelines (2013) (54)
- Positron emission tomography and neuropathologic estimates of fibrillar amyloid-β in a patient with Down syndrome and Alzheimer disease. (2011) (53)
- Tau is reduced in AD plasma and validation of employed ELISA methods. (2012) (53)
- Successes and Failures for Drugs in Late-Stage Development for Alzheimer’s Disease (2013) (52)
- Increased Alzheimer's disease neuropathology is associated with type 2 diabetes and ApoE ε.4 carrier status. (2013) (52)
- The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory (2019) (52)
- Do cholinergic therapies have disease-modifying effects in Alzheimer’s disease? (2006) (52)
- Increasing Precision of Clinical Diagnosis of Alzheimer's Disease Using a Combined Algorithm Incorporating Clinical and Novel Biomarker Data (2017) (51)
- Nicotinic Acetylcholine Receptor Agonists for the Treatment of Alzheimer's Dementia: An Update. (2018) (50)
- Early Detection of Mild Cognitive Impairment (MCI) in Primary Care (2020) (50)
- Multimodal and Multiscale Deep Neural Networks for the Early Diagnosis of Alzheimer’s Disease using structural MR and FDG-PET images (2018) (49)
- Autonomic function, as self-reported on the SCOPA-autonomic questionnaire, is normal in essential tremor but not in Parkinson's disease. (2012) (49)
- Investigational drugs in Alzheimer's disease: current progress (2014) (49)
- Age dependence of brain &bgr;-amyloid deposition in Down syndrome: An [18F]florbetaben PET study (2015) (49)
- Sensor-based balance training with motion feedback in people with mild cognitive impairment. (2016) (48)
- Prevalence of Submandibular Gland Synucleinopathy in Parkinson's Disease, Dementia with Lewy Bodies and other Lewy Body Disorders. (2016) (48)
- Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases. (2009) (47)
- Are certain lifestyle habits associated with lower Alzheimer's disease risk? (2010) (47)
- Cholesterol and Cognitive Performance in Normal Controls and the Influence of Elective Statin Use after Conversion to Mild Cognitive Impairment: Results in a Clinical Trial Cohort (2010) (47)
- BACE1 as a potential biomarker for Alzheimer's disease. (2011) (45)
- Effect of ApoE isoforms on mitochondria in Alzheimer disease (2020) (45)
- Brain biochemistry in autopsied patients with essential tremor (2012) (45)
- Effect of CLU genetic variants on cerebrospinal fluid and neuroimaging markers in healthy, mild cognitive impairment and Alzheimer’s disease cohorts (2016) (44)
- Tau immunotherapies for Alzheimer’s disease (2019) (44)
- Neuronal gene expression correlates of Parkinson's disease with dementia (2008) (43)
- Alzheimer disease periventricular white matter lesions exhibit specific proteomic profile alterations (2013) (43)
- The biochemical aftermath of anti-amyloid immunotherapy (2010) (43)
- Nicotinic receptor losses in dementia with Lewy bodies: comparisons with Alzheimer’s disease (2000) (43)
- Are there differences in cerebral white matter lesion burdens between Parkinson’s disease patients with or without dementia? (2009) (42)
- Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials (2008) (42)
- The use of memantine in dementia with Lewy bodies. (2005) (42)
- PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer’s disease and Lewy body disorders (2014) (42)
- Molecular Differences and Similarities Between Alzheimer’s Disease and the 5XFAD Transgenic Mouse Model of Amyloidosis (2013) (41)
- Olfaction in the Elderly: A Cross-Sectional Analysis Comparing Parkinson's Disease with Controls and Other Disorders (2010) (41)
- Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer's Disease: Results from a Double-Blind, Placebo-Controlled Trial. (2017) (41)
- Neuropathological findings of PSP in the elderly without clinical PSP: possible incidental PSP? (2011) (40)
- Correlation of nicotinic binding with neurochemical markers in Alzheimer's disease (1998) (39)
- Critical Appraisal of Amyloid Lowering Agents in AD (2021) (39)
- The Alzheimer's questionnaire: a proof of concept study for a new informant-based dementia assessment. (2010) (38)
- Cholesterol, copper and Abeta in controls, MCI, AD and the AD cholesterol-lowering treatment trial (ADCLT). (2005) (37)
- Neurochemical profile of dementia pugilistica. (2013) (37)
- Functional Ability Correlates with Cognitive Impairment in Parkinson’s Disease and Alzheimer’s Disease (2007) (36)
- Mining Outcome-relevant Brain Imaging Genetic Associations via Three-way Sparse Canonical Correlation Analysis in Alzheimer’s Disease (2017) (36)
- Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response (2013) (36)
- Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics (2019) (35)
- Corticomuscular coherence is increased in the small postural tremor of Parkinson's disease (2006) (35)
- Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment (2015) (35)
- Rationale for Early Diagnosis of Mild Cognitive Impairment (MCI) supported by Emerging Digital Technologies (2019) (35)
- Unified Staging System for Lewy Body Disorders: Clinicopathologic Correlations and Comparison to Braak Staging. (2019) (35)
- Patients With Alzheimer Disease Have Altered Transmitral Flow (2009) (34)
- Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates. (2014) (34)
- Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer’s disease (MCI and dementia) in primary care: a review and synthesis (2021) (34)
- Presence of Striatal Amyloid Plaques in Parkinson's Disease Dementia Predicts Concomitant Alzheimer's Disease: Usefulness for Amyloid Imaging. (2012) (34)
- Donepezil: potential neuroprotective and disease-modifying effects (2008) (34)
- Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations. (2014) (34)
- Correlation of Clinical Features With Argyrophilic Grains at Autopsy (2009) (33)
- Laughter and crying in neurologic disorders (1994) (33)
- Smoking affects the phenotype of Alzheimer disease (2005) (33)
- Progressive Aphasia with Lewy Bodies (2002) (33)
- Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinson’s Disease Patients (2015) (32)
- Early Detection of Mild Cognitive Impairment (MCI) in an At-Home Setting (2019) (32)
- Potential Peripheral Biomarkers for the Diagnosis of Alzheimer's Disease (2011) (32)
- Abnormal corticomuscular coherence is associated with the small amplitude cortical myoclonus in Parkinson's disease (2003) (31)
- Early investigational drugs targeting tau protein for the treatment of Alzheimer’s disease (2015) (31)
- Challenges to the recognition and assessment of Alzheimer's disease in American Indians of the southwestern United States (2008) (31)
- Bapineuzumab Alters Aβ Composition: Implications for the Amyloid Cascade Hypothesis and Anti-Amyloid Immunotherapy (2013) (31)
- Is There Inflammatory Synergy in Type II Diabetes Mellitus and Alzheimer's Disease? (2012) (30)
- Fornix-Region Deep Brain Stimulation-Induced Memory Flashbacks in Alzheimer's Disease. (2019) (30)
- Validation and diagnostic accuracy of the Alzheimer's questionnaire. (2012) (30)
- Sensitivity to expectancy violations in healthy aging and mild cognitive impairment. (2004) (30)
- Neurochemical markers do not correlate with cognitive decline in the Lewy body variant of Alzheimer disease. (1999) (30)
- Clinical Assessment of Cognitive Decline in Adults with Down Syndrome. (2015) (29)
- Consequences of Aberrant Insulin Regulation in the Brain: Can Treating Diabetes be Effective for Alzheimer’s Disease (2011) (29)
- GBA mutations in Parkinson disease: earlier death but similar neuropathological features (2017) (28)
- Autonomic complaints in patients with restless legs syndrome. (2013) (28)
- Pseudoneurologic syndromes: recognition and diagnosis. (1998) (28)
- Differences in Cerebrospinal Fluid Biomarkers between Clinically Diagnosed Idiopathic Normal Pressure Hydrocephalus and Alzheimer’s Disease (2014) (28)
- Genetic studies of plasma analytes identify novel potential biomarkers for several complex traits (2016) (28)
- The impact of apolipoprotein E4 on cause of death in Alzheimer's disease (1997) (27)
- Age-Dependent Relationship Between Plasma Aβ40 and Aβ42 and Total Tau Levels in Cognitively Normal Subjects (2019) (27)
- Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. (2010) (27)
- Instrumented Trail-Making Task to Differentiate Persons with No Cognitive Impairment, Amnestic Mild Cognitive Impairment, and Alzheimer Disease: A Proof of Concept Study (2016) (27)
- Preliminary Assessment of Intravoxel Incoherent Motion Diffusion‐Weighted MRI (IVIM‐DWI) Metrics in Alzheimer's Disease (2020) (26)
- Women can bear a bigger burden: ante- and post-mortem evidence for reserve in the face of tau (2020) (26)
- Alzheimer’s disease beyond amyloid: strategies for future therapeutic interventions (2020) (26)
- Cortical phosphorylated α‐Synuclein levels correlate with brain wave spectra in Parkinson's disease (2016) (26)
- Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimer's pathology not α-synuclein pathology (2017) (26)
- Accelerated functional brain aging in pre-clinical familial Alzheimer’s disease (2021) (25)
- Open Peer Commentary to “Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019” (2020) (25)
- Clinical drug development for dementia with Lewy bodies: past and present (2019) (25)
- Lewy body pathology in Alzheimer's disease: A clinicopathological prospective study (2018) (25)
- 5HT6 Antagonists in the Treatment of Alzheimer’s Dementia: Current Progress (2018) (25)
- The influence of Apolipoprotein E genotype on regional pathology in Alzheimer’s disease (2013) (24)
- Amyloid Imaging: Poised for Integration into Medical Practice (2016) (24)
- Donepezil: potential neuroprotective and disease-modifying effects. (2008) (24)
- Tau immunoreactivity in peripheral tissues of human aging and select tauopathies (2019) (24)
- Informant-reported cognitive symptoms that predict amnestic mild cognitive impairment (2012) (23)
- Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient. (2011) (23)
- Age dependence of brain β-amyloid deposition in Down syndrome (2015) (22)
- Correlation of nicotinic receptor binding with clinical and neuropathological changes in Alzheimer's disease and dementia with Lewy bodies (2001) (21)
- 18F-florbetapir Positron Emission Tomography–determined Cerebral &bgr;-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery (2018) (21)
- Cascaded Multi-view Canonical Correlation (CaMCCo) for Early Diagnosis of Alzheimer’s Disease via Fusion of Clinical, Imaging and Omic Features (2017) (20)
- Severe hyposmia distinguishes neuropathologically confirmed dementia with Lewy bodies from Alzheimer’s disease dementia (2019) (20)
- Extrapyramidal Signs by Dementia Severity in Alzheimer Disease and Dementia With Lewy Bodies (2013) (20)
- Abnormal serum concentrations of proteins in Parkinson's disease. (2009) (20)
- Positive florbetapir PET amyloid imaging in a subject with frequent cortical neuritic plaques and frontotemporal lobar degeneration with TDP43-positive inclusions. (2014) (20)
- Correlations between SPECT regional cerebral blood flow and psychometric testing in patients with Alzheimer's disease. (1997) (19)
- Amyloid accumulation in Down syndrome measured with amyloid load (2020) (19)
- Palliative care for advanced Alzheimer's and dementia : guidelines and standards for evidence-based care (2011) (19)
- KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimer’s disease (2021) (19)
- Effects of donepezil treatment on rat nicotinic acetylcholine receptor levels in vivo and in vitro. (2004) (19)
- A Novel Joint Brain Network Analysis Using Longitudinal Alzheimer’s Disease Data (2019) (19)
- Pathological correlates of cognitive decline in Alzheimer's disease. (2007) (19)
- The effect of statins on rate of cognitive decline in mild cognitive impairment (2017) (18)
- Intracranial Atherosclerosis as a contributing factor to Alzheimer's disease Dementia (2009) (18)
- Can platelet BACE1 levels be used as a biomarker for Alzheimer's disease? Proof-of-concept study (2013) (18)
- Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease (2019) (18)
- A cellular model of amyloid precursor protein processing and amyloid-β peptide production (2014) (18)
- Comparison of neuropathology in Parkinson's disease subjects with and without deep brain stimulation (2017) (18)
- Florbetaben for PET Imaging of Beta-Amyloid Plaques in the Brain (2014) (17)
- Is the functional decline of Parkinson's disease similar to the functional decline of Alzheimer's disease? (2005) (17)
- Predicting alpha-synuclein pathology by REM sleep behavior disorder diagnosis. (2018) (17)
- Health Care Utilization and Costs Among Patients With AD With and Without Dysphagia (2013) (17)
- Parkinson's disease, cortical dysfunction, and alpha‐synuclein (2011) (17)
- Clinical Characterization of Mild Cognitive Impairment as a Prodrome to Dementia With Lewy Bodies (2015) (17)
- Genome-wide association analysis of hippocampal volume identifies enrichment of neurogenesis-related pathways (2016) (16)
- Reduced clinical and postmortem measures of cardiac pathology in subjects with advanced Alzheimer's Disease (2011) (16)
- Early Stages of Alzheimer's Disease: Evolving the Care Team for Optimal Patient Management (2021) (16)
- MCLENA-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease (2019) (16)
- The nicotinic acetylcholine receptor: smoking and Alzheimer's disease revisited. (2012) (15)
- Clinical Features of Severe Dementia: Staging (2006) (15)
- Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer’s Dementia (2018) (15)
- Does apolipoprotein E (Apo-E) genotype influence nicotinic receptor binding in Alzheimer's disease (2001) (15)
- Essential Tremor in the Elderly and Risk for Dementia (2014) (15)
- Sex and post-menopause hormone therapy effects on hippocampal volume and verbal memory (2017) (15)
- Advance in Plasma AD Core Biomarker Development: Current Findings from Immunomagnetic Reduction-Based SQUID Technology (2019) (15)
- Brain structures and networks responsible for stimulation‐induced memory flashbacks during forniceal deep brain stimulation for Alzheimer's disease (2021) (15)
- Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and in vitro (2008) (15)
- Subjects harboring presenilin familial Alzheimer's disease mutations exhibit diverse white matter biochemistry alterations. (2013) (15)
- Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity (2013) (15)
- Polypharmacy in an Elderly Population: Enhancing Medication Management Through the Use of Clinical Decision Support Software Platforms (2019) (14)
- Length of stay in skilled nursing facilities is longer for patients with dementia. (2003) (14)
- Amyloid-ß and Treatment Opportunities for Alzheimer's Disease (2000) (14)
- SMG1 Identified as a Regulator of Parkinson’s Disease-Associated alpha-Synuclein through siRNA Screening (2013) (14)
- Absence of effect of chronic nicotine administration on amyloid beta peptide levels in transgenic mice overexpressing mutated human APP (Sw, Ind) (2008) (14)
- Early and Mild Phases of Primary Progressive Aphasia: A Case Series. (2017) (14)
- Biochemical Assessment of Precuneus and Posterior Cingulate Gyrus in the Context of Brain Aging and Alzheimer’s Disease (2014) (14)
- Development of a specific ELISA to measure BACE1 levels in human tissues (2011) (14)
- Is Cholesterol a Culprit in Alzheimer's Disease? (2003) (14)
- Recent Perspectives on APP, Secretases, Endosomal Pathways and How they Influence Alzheimer’s Related Pathological Changes in Down Syndrome (2013) (13)
- Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study. (2018) (13)
- Combination Therapy for Alzheimer’s Disease: Perspectives of the EU/US CTAD Task Force (2019) (13)
- Deep brain stimulation targeting the fornix for mild Alzheimer dementia: design of the ADvance randomized controlled trial (2015) (13)
- Relationship of amyloid beta and neurofibrillary tau deposition in Neurodegeneration in Aging Down Syndrome (NiAD) study at baseline (2020) (12)
- Studies on the effect of the apolipoprotein E genotype on the lipid profile in Alzheimer's disease. (2006) (12)
- Incidental Lewy body disease: Electrophysiological findings suggesting pre-clinical Lewy body disorders (2011) (12)
- Long-Term Storage Effects on Stability of Aβ1–40, Aβ1–42, and Total Tau Proteins in Human Plasma Samples Measured with Immunomagnetic Reduction Assays (2019) (12)
- Multicentre phase 3 trial on florbetaben for beta-amyloid brain PET in Alzheimer's disease (2012) (12)
- Disease-modifying approaches to Alzheimer’s disease: Challenges and opportunities—Lessons from donepezil therapy (2008) (12)
- A semi-mechanism approach based on MRI and proteomics for prediction of conversion from mild cognitive impairment to Alzheimer’s disease (2016) (12)
- Statins to treat Alzheimer’s disease: an incomplete story (2012) (11)
- The Cause of Alzheimer’s Disease: The Theory of Multipathology Convergence to Chronic Neuronal Stress (2022) (11)
- Neuropathological and biochemical assessments of an Alzheimer's disease patient treated with the γ-secretase inhibitor semagacestat. (2014) (11)
- Drug Design and Discovery in Alzheimer’s Disease (2014) (11)
- Regional neuropathology distribution and verbal fluency impairments in Parkinson's disease. (2019) (11)
- Converging mediators from immune and trophic pathways to identify Parkinson disease dementia (2016) (10)
- Aquatic Therapy and Alzheimer's Disease (2013) (10)
- Does informant-based reporting of cognitive symptoms predict amyloid positivity on positron emission tomography? (2019) (10)
- Non-Amyloid Approaches to Disease Modification for Alzheimer’s Disease: An EU/US CTAD Task Force Report (2020) (10)
- A safety, tolerability and pharmacokinetic study of dimebon in patients with Alzheimer's disease already receiving donepezil (2009) (10)
- Development, Application, and Results from a Precision-medicine Platform that Personalizes Multi-modal Treatment Plans for Mild Alzheimer’s Disease and At-risk Individuals (2018) (10)
- Quantitative Appraisal of Ventricular Cerebrospinal Fluid Biomarkers in Neuropathologically Diagnosed Parkinson’s Disease Cases Lacking Alzheimer’s Disease Pathology (2013) (10)
- Comparative Analysis of the Alzheimer Questionnaire (AQ) With the CDR Sum of Boxes, MoCA, and MMSE (2014) (10)
- Improved diagnosis of Parkinson's disease from a detailed olfactory phenotype (2017) (10)
- The impact of PICALM genetic variations on reserve capacity of posterior cingulate in AD continuum (2016) (10)
- Neuropathological Findings in Parkinson's Disease With Mild Cognitive Impairment (2020) (10)
- Phase III trial results for the amyoid PET imaging agent Florbetapir F 18 (18F-AV-45): imaging to histopathologic correlations in an end-of-life human subject study (2010) (10)
- Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease (2022) (9)
- Added value and limitations of amyloid-PET imaging: review and analysis of selected cases of mild cognitive impairment and dementia (2017) (9)
- BACE1 levels by APOE genotype in non-demented and Alzheimer's post-mortem brains. (2013) (9)
- Histopathology and Florbetaben PET in Patients Incorrectly Diagnosed with Alzheimer's Disease. (2017) (9)
- Mapping autonomic, mood, and cognitive effects of hypothalamic region deep brain stimulation. (2021) (9)
- Primary prevention recommendations to reduce the risk of cognitive decline (2022) (9)
- Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region (2016) (9)
- Feasibility Study: Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases (2015) (9)
- Unawareness of Hyposmia in Elderly People With and Without Parkinson's Disease (2016) (9)
- On cholesterol levels and statins in cognitive decline and Alzheimer disease: progress and setbacks. (2009) (9)
- A telescope GWAS analysis strategy, based on SNPs-genes-pathways ensamble and on multivariate algorithms, to characterize late onset Alzheimer’s disease (2020) (8)
- Broader Considerations of Higher Doses of Donepezil in the Treatment of Mild, Moderate, and Severe Alzheimer's Disease (2011) (8)
- Prevalence of Hippocampal Sclerosis in a Clinicopathologically Characterized Cohort (2013) (8)
- APOE ε4/ε4 homozygotes with early Alzheimer's disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline (2020) (8)
- Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer’s dementia? (2018) (8)
- Interactions of stroke, nonsteroidal anti-inflammatory drugs, and APOE status in dementia risk (2008) (8)
- Lewy Body Dementia Association’s Research Centers of Excellence Program: Inaugural Meeting Proceedings (2019) (8)
- 31. Staging Dementia (2010) (7)
- Correlation between Alzheimer’s disease and type 2 diabetes using non-negative matrix factorization (2021) (7)
- Voxel-based morphometry in Alzheimer's patients (2006) (7)
- Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium (2021) (7)
- Clinical Effects of Oral Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification. (2017) (7)
- Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume (2022) (6)
- Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer’s disease (2022) (6)
- Predicting Alzheimer’s disease progression using multi-modal deep learning approach (2019) (6)
- Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference (2018) (6)
- KIF6 719Arg allele is associated with statin effects on cholesterol levels in amnestic mild cognitive impairment and Alzheimer's disease patients. (2012) (5)
- Development and Validation of the Alzheimer's Questionnaire (AQ). (2015) (5)
- Is diabetes associated with increased pathological burden in Alzheimer's disease? (2021) (5)
- The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory (2019) (5)
- Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” A national registry to identify a cohort for Alzheimer's disease prevention studies (2009) (5)
- Possible Alzheimer's disease in an apolipoprotein E2 homozygote. (2009) (5)
- Investigational drugs for the treatment of AD: what can we learn from negative trials? (2011) (5)
- P4-389: An oral antagonist of the receptor for advanced glycation end products (RAGE) is safe and well-tolerated in the treatment of Alzheimer's disease: Results from a phase II study (2008) (5)
- Neurofibrillary tau depositions emerge with subthreshold cerebral beta-amyloidosis in down syndrome (2021) (5)
- Age-Related Atrophy and Compensatory Neural Networks in Reading Comprehension (2019) (5)
- An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in female patients with Alzheimer’s disease (2022) (5)
- Multicentre phase 3 trial on florbetaben for β-amyloid brain PET in Alzheimer disease (2012) (4)
- Review of Advanced Drug Trials Focusing on the Reduction of Brain Beta-Amyloid to Prevent and Treat Dementia (2022) (4)
- Dissection of the polygenic architecture of neuronal Aβ production using a large sample of individual iPSC lines derived from Alzheimer’s disease patients (2022) (4)
- NEUROFIBRILLARY TANGLE PREDOMINANT DEMENTIA: CLINICAL AND PATHOLOGICAL DESCRIPTION IN A CASE SERIES (2016) (4)
- Neuropsychological Correlates of the Alzheimer's Questionnaire. (2015) (4)
- Latrepirdine for Alzheimer’s disease: trials and tribulations (2010) (4)
- An Appraisal of Novel Biomarkers for Evaluating and Monitoring Neurologic Diseases: Editorial Introduction (2016) (4)
- Occipital and Cingulate Hypometabolism are Significantly Under-Reported on 18-Fluorodeoxyglucose Positron Emission Tomography Scans of Patients with Lewy Body Dementia (2018) (4)
- Featured Articles Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease (2009) (4)
- Amyloid-beta and treatment opportunities for Alzheimer's disease. (2000) (4)
- Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress (2019) (4)
- Effect of CLU genetic variants on cerebrospinal fluid and neuroimaging markers in healthy, mild cognitive impairment and Alzheimer’s disease cohorts (2016) (4)
- Case series of clinically probable dementia with Lewy bodies in two Native Americans. (2004) (3)
- Detecting Alzheimer disease before it happens (2008) (3)
- AZELIRAGON PHASE 2B SURVIVAL ANALYSIS SUPPORTS BENEFICIAL EFFECTS ON DELAYING TIME TO COGNITIVE DETERIORATION IN PATIENTS WITH MILD ALZHEIMER'S DISEASE (2016) (3)
- Neurofibrillary Tangle Predominant Dementia: Clinical andPathological Description in a Case Series (2016) (3)
- The use of informant-based questionnaires in differentiating mild cognitive impairment from normal aging (2012) (3)
- Should the guidelines for monitoring serum cholesterol levels in the elderly be re-evaluated? (2002) (3)
- Dementia with Lewy bodies: emerging drug targets and therapeutics (2021) (3)
- Glucose metabolism patterns: A potential index to characterize brain ageing and predict high conversion risk into cognitive impairment (2022) (3)
- COR388 (atuzaginstat): an investigational gingipain inhibitor for the treatment of Alzheimer disease (2022) (3)
- Florbetapir F 18 (18F-AV-45) PET amyloid imaging predicts progression of cognitive impairment: A longitudinal clinical follow up study (2010) (3)
- What Promises the CJD Diagnosis in a Case of Rapidly Progressive Dementia? (2018) (3)
- Rationale and strategy for thalidomide as a BACE 1 inhibitor for a phase II randomized clinical trial in mild-to-moderate Alzheimer's disease (2010) (3)
- Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease (2020) (3)
- Correction: Profiles of Extracellular miRNA in Cerebrospinal Fluid and Serum from Patients with Alzheimer's and Parkinson's Diseases Correlate with Disease Status and Features of Pathology (2014) (3)
- Challenges and Opportunities with Causal Discovery Algorithms: Application to Alzheimer’s Pathophysiology (2020) (3)
- Does Informant-Based Reporting of Cognitive Decline Correlate with Age-Adjusted Hippocampal Volume in Mild Cognitive Impairment and Alzheimer’s Disease? (2021) (3)
- Corrigendum: Age-Dependent Relationship Between Plasma Aβ40 and Aβ42 and Total Tau Levels in Cognitively Normal Subjects (2019) (2)
- A prospective study on gait dominant normal pressure hydrocephalus (2019) (2)
- P2-373: Chronic rivastigmine administration reduces beta-amyloid levels in a transgenic mouse model for Alzheimer's disease (2008) (2)
- Pathologically Confirmed Alzheimer's Disease in APOE ɛ2 Homozygotes is Rare but Does Occur. (2018) (2)
- Non-Amyloid Approaches to Disease Modification for Alzheimer's Disease: An EU/US CTAD Task Force Report. (2020) (2)
- Clinicopathologic Correlations in 172 Cases of REM Sleep Behavior Disorder ± a Coexisting Neurologic Disorder (PL01.003) (2013) (2)
- Recruitment and Retention Strategies for Clinical Trials in Alzheimer’s Disease (2003) (2)
- A strong concordance between [F-18]flutemetamol PET and amyloid-beta pathology demonstrated in brain autopsy and in-vivo cortical biopsy trials (2012) (2)
- Echocardiography vortex formation time reveal cardiac diastolic transmitral flow dysfunction in Alzheimer's disease patients (2009) (2)
- Ttp488: From futile to fast track (2015) (2)
- Novel Therapeutics in Alzheimer's Disease (2012) (2)
- Editorial: Current and Emerging Therapeutics in AD. (2017) (2)
- Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome: A Phase 1b Randomized Clinical Trial. (2022) (2)
- Probable Early-Onset Alzheimer’s Disease in an Apolipoprotein E2 Homozygote (2010) (2)
- Florbetapir PET, FDG-PET and MRI in people with Down syndrome with and without symptomatic Alzheimer's disease (2013) (2)
- The effect of healthy aging and mild cognitive impairment on semantic ambiguity detection (2013) (2)
- The role of statins in delaying Alzheimer’s disease. Circulating cholesterol levels, ApoE genotype and initial dementia severity influence the level of benefit produced by atorvastatin in mild-to-moderate AD: Results of the ADCLT (2005) (2)
- Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study (2023) (2)
- Commentary on “Developing a national strategy to prevent dementia: Leon Thal Symposium 2009.” Creating a national database for successful aging (2010) (2)
- Therapeutic considerations for APOE and TOMM40 in Alzheimers disease: A tribute to Allen Roses MD (2020) (2)
- KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimer's Disease Patients (2013) (2)
- Are Clinical Certainty Ratings Helpful in the Diagnosis of Parkinson's Disease? (2018) (1)
- Ttp488 path to registration: Leveraging enrichment strategies (2015) (1)
- Geriatric Neurology: Nair/Geriatric (2014) (1)
- Heart rate variability as a screening tool for Parkinson’s disease has age-dependent performance (P1.110) (2017) (1)
- Optimal deep brain stimulation sites and networks for stimulation of the fornix in Alzheimer’s disease (2022) (1)
- P4-396: Arizona Alzheimer's research registry part one: Rationale and design (2008) (1)
- Biomarker-based diagnosis of preclinical Alzheimer disease: time for the clinic? (2023) (1)
- Approach to the Geriatric Neurology Patient: The Neurologic Examination (2014) (1)
- P4-371: Arizona Alzheimer's research registry part two progress and findings from year one (2008) (1)
- DIFFERENCE IN COGNITIVE DECLINE BETWEEN COMBINATION THERAPY WITH DONEPEZIL AND INTEPIRDINE (RVT-101) AND DONEPEZIL MONOTHERAPY: RESULTS FROM A 48 WEEK MULTINATIONAL PLACEBO-CONTROLLED STUDY IN MILD TO MODERATE ALZHEIMER'S DISEASE (2017) (1)
- Response to Parkinnen et al. and Jellinger (2009) (1)
- Lecanemab (BAN2401): an anti–beta-amyloid monoclonal antibody for the treatment of Alzheimer disease (2023) (1)
- Longitudinal Assessment of Intravoxel Incoherent Motion Diffusion‐Weighted MRI Metrics in Cognitive Decline (2022) (1)
- [F-18]AV-1451 PET IN NON-DEMENTED ADULTS WITH DOWN SYNDROME IS RELATED TO BOTH AMYLOID AND COGNITION (2017) (1)
- A phase II double-blind, placebo-controlled randomized trial of an escalating dose of thalidomide in the treatment of Alzheimer's disease: Baseline characteristics (2013) (1)
- Age-related frontal lobe compensation during novelty detection (2013) (1)
- SALIVARY AMYLOID-BETA PROTEIN LEVELS CAN DIAGNOSE ALZHEIMER DISEASE AND PREDICT ITS FUTURE ONSET (2017) (1)
- SINGLE ENDPOINT FOR NEW DRUG APPROVALS FOR ALZHEIMER ’ S DISEASE (2017) (1)
- Commentary on “The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Design and baseline characteristics” (2008) (1)
- ASSESSING POTENTIALS OF PLASMA AMYLOID BETA 42 AND TAU LEVELS FOR ALZHEIMER'S DISEASE DIAGNOSIS BY TESTING IMMUNOMAGNETIC REDUCTION TECHNOLOGY IN A SUN CITY COHORT (2017) (1)
- Author Correction: Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease (2021) (1)
- Detection of beta-Amyloid by Florbetaben PET: Histopathological Verification in a Global Phase 3 Clinical Trial (2012) (1)
- Clinicopathological Correlation: Dopamine and Amyloid PET Imaging with Neuropathology in Three Subjects Clinically Diagnosed with Alzheimer's Disease or Dementia with Lewy Bodies. (2021) (1)
- The importance of genomics in advancing the diagnosis and treatment of dementia (2022) (1)
- Clinical Features of Patients with Concomitant Parkinson's Disease and Progressive Supranuclear Palsy Pathology (2015) (1)
- Clinical and Neuropathological Correlates of Visual Hallucinations in Parkinsonism (2013) (1)
- Comprar The Alzheimers Answer: Reduce Your Risk and Keep Your Brain Healthy | Marwan Sabbagh | 9780470044940 | Wiley (2008) (1)
- A Pilot Phase IV Open-Label Study Investigating the Safety and Tolerability of Donepezil 23 mg Once Daily in Patients with Moderate to Severe AD Switched from Exelon Patch 9 . 5 mg Daily (2015) (1)
- Apolipoprotein E4 serum concentration for increased sensitivity and specificity of diagnosis of drug treated Alzheimer's disease patients vs. drug treated parkinson's disease patients vs. age-matched normal controls. (2012) (1)
- Editorial: A Time of Transition of Alzheimer's Disease in the Advent of Anti-Amyloid Monoclonal Antibodies (2021) (1)
- Relationship of Florbetapir F18 PET Amyloid Plaque Neuroimaging with Future Cognitive Decline over 36 Months (2013) (1)
- Application of the Changing Therapies for Alzheimer's Disease in Clinical Practice (1998) (1)
- Alzheimer's disease subjects carrying the APOE4 allele have lower brain BACE1 levels than APOE3 carriers (2011) (0)
- P1-283 Ethnic differences in MRI scans among Alzheimer’s disease patients and unaffected siblings in the MIRAGE Study (2006) (0)
- Neuropathological Validation of the Alzheimer’s Questionnaire (2022) (0)
- Fundamental Statistical Methods for Analysis of Alzheimer's and Other Neurodegenerative Diseases (2020) (0)
- P3-006 ASSESSMENT OF THE EFFECTS OF MEMANTINE IN ALZHEIMER’S DISEASE WITH CHRONIC DAILY HEADACHE (2018) (0)
- Studying the natural history of frontotemporal lobar degeneration (FTLD): The ARTFL LEFFTDS longitudinal FTLD (ALLFTD) protocol (2020) (0)
- Erythrocyte cr1 and its relationship to Alzheimer's disease pathogenic mechanisms and immunization strategies (2015) (0)
- Significant elevation of plasma BACE in AD and MCI patients (2011) (0)
- Negative Florbetaben PET Scan Excludes the Presence of Amyloid Pathology (2014) (0)
- Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer’s Dementia (2018) (0)
- Imaging of the Geriatric Brain (2014) (0)
- Sensitivity to change and prediction of global change for the Alzheimer’s Questionnaire (2015) (0)
- Concurrent validity of the Alzheimer's Questionnaire (AQ) (2012) (0)
- ENHANCING MEDICATION MANAGEMENT THROUGH THE USE OF CLINICAL DECISION SUPPORT SOFTWARE PLATFORMS (2018) (0)
- Is Type 2 diabetes mellitus associated with an increased pathological burden in clinically and pathologically diagnosed Alzheimer's dementia? (2020) (0)
- Frequently Asked Questions About Alzheimer's (2008) (0)
- Preclinical testing of lenalidomide as anti-amyloid treatment for Alzheimer's disease (2012) (0)
- P3-258 Effects of cholinesterase inhibitors on nicotinic acetylcholine receptor levels in the rat (2006) (0)
- Nevada exploratory Alzheimer’s disease research center: Advancing dementia care in rural communities (2021) (0)
- Severe multimorbidity is prevalent in those with cognitive decline, which challenges neurologists and family physicians: A clinical decision‐support software (CDSS) platform provides guidance (2020) (0)
- Inflammatory Mechanisms in Alzheimer'S Disease and Other Neurodegenerative Disorders (2008) (0)
- A pilot phase IV open label study investigating the safety and tolerability of switching from the Exelon patch 9.5mg daily to Aricept 23mg daily in patients with moderate to severe AD (2011) (0)
- Comparison of [18F]Flutemetamol PET Image Interpretation with Clinical Diagnosis of Alzheimer's Disease: Neuritic Plaque Density Standard Based on Consortium To Establish a Registry for Alzheimer's Disease Criteria (IN3-2.001) (2013) (0)
- Can the KIF6 polymorphism predict statin responsiveness in prodromal and symptomatic Alzheimer's disease? (2011) (0)
- Listening session with the US Food and Drug Administration, Lewy Body Dementia Association, and an expert panel (2023) (0)
- THE EFFECT OF STATINS ON RATE OF COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT (2016) (0)
- Evaluation of the efficacy and safety of florbetaben PET in adults with down syndrome (2011) (0)
- Recommendations of the International Working Group for the clinical diagnosis of Alzheimer’s disease (2021) (0)
- Acknowledgement to Authors, Referees and Readers 2019 (2018) (0)
- Does the presence of type II Diabetes affect cognitive decline in Alzheimer’s Disease Dementia? (2022) (0)
- Age-dependent 18-F florbetaben brain PET uptake in adults with Down's syndrome (2013) (0)
- Risk of Developing Dementia in Essential Tremor (S53.004) (2013) (0)
- Autonomic Sudomotor Dysfunction in Alzheimers Disease (2003) (0)
- ADDRESSING POLYPHARMACY ISSUES IN AN ELDERLY POPULATION WITH COGNITIVE IMPAIRMENT USING A PRECISION-MEDICINE PLATFORM (2019) (0)
- PROSPECTS OF USING PLASMA AB42 AND TAU PROTEIN IN IDENTIFYING ALZHEIMER’S DISEASE DEMENTIA IN CLINICS (2016) (0)
- Editorial Introduction to the Special Issue from the International Symposium on Biomarkers for Alzheimer’s Disease and Related Disorders (2017) (0)
- Commentary on “Design of comprehensive Alzheimer's disease centers to address unmet national needs” (2010) (0)
- P1-399: Plasma-based biomarkers differentiate Alzheimer's disease from control subjects (2008) (0)
- DEVELOPMENT, APPLICATION, AND RESULTS FROM A PRECISION-MEDICINE PLATFORM THAT PERSONALIZES MULTI-MODAL CARE PLANS FOR MILD ALZHEIMER'S DISEASE AND THOSE AT-RISK (2018) (0)
- Acknowledgement to Authors, Referees, and Readers (2018) (0)
- IMR-ASSAYED PLASMA Aβ42 AND T-TAU CLASSIFIED MILD COGNITIVE IMPAIRED AND MILD ALZHEIMER’S DISEASE SUBJECTS WITH HIGH ACCURACIES IN A MULTI-COUNTRY CROSS-SECTIONAL STUDY (2019) (0)
- OBSERVATIONS ON THE FREQUENCY OF DEPRESSION AND MEDICATIONS IN AN APOE-ε4 VERSUS NON-APOE-ε4 POPULATION (2018) (0)
- Neuropathological outcome of prospectively followed normal elderly brain bank volunteers (2013) (0)
- P2-168 Can neuropathological and nicotinic receptor binding differences distinguish mild cognitive impairment from Alzheimer’s disease and normal aging? (2006) (0)
- Neurology and Therapy: Looking Back on 2018 and Forward to 2019 (2019) (0)
- THE MILD COGNITIVE IMPAIRMENT OF PRIMARY PROGRESSIVE APHASIA: A CASE SERIES (2016) (0)
- P3-004 The lipid profile in Alzheimer's disease (2004) (0)
- FUNCTIONAL, GLOBAL, AND COGNITIVE DECLINE CORRELATES TO ACCUMULATION OF ALZHEIMERʼS PATHOLOGY.: 9. (2006) (0)
- PATHOLOGICALLY CONFIRMED AD IN APOE ε2 HOMOZYGOTES IS RARE BUT DOES OCCUR (2018) (0)
- Techniques for histopathological verification of florbetaben PET in a global phase III clinical trial (2012) (0)
- P3.130 Serum proteomic biomarkers for the diagnosis of Parkinson's disease (2009) (0)
- OBSERVATIONS ON THE INFLUENCE OF DRUG INTERACTIONS ON COMPREHENSIVE CARE PLANS GENERATED TO ADDRESS COGNITIVE DECLINE (2018) (0)
- Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics (2019) (0)
- DOES INFORMANT BASED REPORTING OF COGNITIVE SYMPTOMS RELATE TO AMYLOID POSITIVITY ON POSITRON EMISSION TOMOGRAPHY? (2019) (0)
- The complexity of DLB: U.S.‐based Dementia with Lewy Body Consortium (2020) (0)
- P3-114: Survey of variations in the administration and scoring of the ADAS-Cog (2008) (0)
- Type 2 diabetes is associated with increased Alzheimer’s disease neuropathology in ApoE ε 4 Carriers (2014) (0)
- Author ' s response to reviews Title : Clinical and Postmortem Measures of Cardiac Pathology in Subjects with Alzheimer ' s Disease (2010) (0)
- The 5th International Conference on Alzheimer's Disease and related disorders in the Middle East, 15-17 May 2009, Limassol Cyprus. (2012) (0)
- Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal dementia and GRN mutations : a genome-wide association study (2018) (0)
- Lenalidomide as an antineuroinflammatory and BACE1 inhibitor: Pilot study on APP23 mice (2013) (0)
- Author ' s response to reviews Title : Clinical and Postmortem Measures of Cardiac Pathology in Subjects with Alzheimer ' s Disease (2010) (0)
- Author's response to reviews Title: Informant-Reported Cognitive Symptoms That Predict Amnestic Mild Cognitive Impairment Authors: (2011) (0)
- Author's response to reviews Title: Informant-Reported Cognitive Symptoms That Predict Amnestic Mild Cognitive Impairment Authors: (2011) (0)
- Comparison of Visual and Quantitative 18F-Florbetaben PET Scan Assessment (2015) (0)
- Clinical Features Predict Lewy Body Pathology and Differentiate between Different Pathologies: A Clinical-Pathologic Prospective Study (P6.231) (2016) (0)
- Reduction of anticholinergic cognitive burden (ACB) in primary care using a clinical decision‐support software (CDSS) platform (2020) (0)
- KIF6 719Arg carrier status association with homocysteine and C-reactive protein in mild cognitive impairment and Alzheimer's disease (2013) (0)
- CORRELATION BETWEEN PLASMA AMYLOID BETA AND TAU CONCENTRATIONS IN COGNITIVELY NORMAL CONTROLS AGED 24 TO 91 YEARS OLD (2018) (0)
- Erratum to: Successes and Failures for Drugs in Late-Stage Development for Alzheimer’s Disease (2013) (0)
- How does diabetes affect plaque and tangle pathology in Alzheimer's Disease? (2011) (0)
- Florbetapir PET Imaging Predicts Postmortem Amyloid Burden in Alzheimer's Disease Despite Presence of Other Neuropathologies (2013) (0)
- Informant‐based report of cognitive decline correlates with age‐adjusted hippocampal volume in mild cognitive impairment and Alzheimer's dementia? (2020) (0)
- Clinicopathologically Characterized Cohort (2013) (0)
- Prevalence Of Lewy-Type Synucleinopathy In The Submandibular Gland Of Subjects With Neuropathologically-Confirmed Dementia With Lewy Bodies. (S38.007) (2014) (0)
- Significantly altered BACE1 levels have been found in the blood of Alzheimer's disease and MCI subjects (2009) (0)
- P-108 Creation and validation of an Alzheimer’s questionnaire (2007) (0)
- OBSERVATIONS ON COACHING IN MANAGING LIFESTYLE AND BEHAVIORAL CHANGES IN PERSONALIZED MULTIMODAL CARE PLANS FOR COGNITIVE IMPAIRMENT (2018) (0)
- A blood-based signature of cerebrospinal fluid Aβ1–42 status (2019) (0)
- P3-115: Reitan trail making test versus color trails test performance in American Indians (2008) (0)
- ACI‐24 vaccine in adults with Down syndrome (2020) (0)
- Gearing up for the future: Exploring facilitators and barriers to inform clinical trial design in frontotemporal lobar degeneration (2021) (0)
- P3-165 MRI traits are heritable among Alzheimer disease cases and their siblings in the MIRAGE Study (2006) (0)
- Deep brain stimulation targeting the fornix for mild Alzheimer’s disease: Initial results of the advance randomized controlled trial (2015) (0)
- GenEpi: gene-based epistasis discovery using machine learning (2020) (0)
- DEVELOPMENT, APPLICATION, AND RESULTS FROM A CLINICAL INFORMATICS PLATFORM THAT ENABLES A MULTI-MODAL TREATMENT PROTOCOL FOR ALZHEIMER'S DISEASE (AD) (2017) (0)
- Prospective clinical validation of the use of protein biomarkers from newly drawn patient sera for diagnosis of Alzheimer's disease (2010) (0)
- Cholesterol, copper and statin therapy in Alzheimer's disease (2005) (0)
- Frontal and Hippocampal Tangles and Plaque Density Are Associated with Anosognosia in Alzheimer Disease (P05.051) (2012) (0)
- The trend of disruption in the functional brain network topology of Alzheimer’s disease (2021) (0)
- Are Certain Lifestyle Habits Associated with Lower Alzheimer's Disease Risk? (2015) (0)
- Transcranial Dopplerultrasoundbloodflowvelocityandpulsatilityindex as systemic indicators for Alzheimer's disease (2011) (0)
- Roadmap to implementation of a fully automated blood‐based biomarker test to facilitate diagnosis and treatment in early Alzheimer’s disease (2022) (0)
- Neuropathological Correlates of Visual Hallucinations in Parkinsonism (S03.006) (2013) (0)
- Neurodegeneration: the First IBRO-Middle East Neuroscience Conference. (2013) (0)
- The Alzheimers Answer: Reduce Your Risk and Keep Your Brain Healthy (2008) (0)
- INSTRUMENTED TRAIL-MAKING TASK (ITMT) TO ASSESS DUAL-TASK AND COGNITIVE IMPAIRMENT IN ELDERLY (2017) (0)
- The women’s Alzheimer’s prevention center at Cleveland Clinic: Centering women in Alzheimer’s prevention care and research (2021) (0)
- Preliminary Assessment of Intravoxel Incoherent Motion Diffusion‐Weighted MRI ( IVIM‐DWI ) Metrics in Alzheimer's Disease (2020) (0)
- Title The influence of Apolipoprotein E genotype on regional pathology in Alzheimer ' s disease (2013) (0)
- Is it appropriate to include Alzheimer's disease patients in non-AD clinical research? (2009) (0)
- Striatal amyloid plaque density predicts braak neurofibrillary tangle stage and clinicopathological Ad: Implications for amyloid imaging (2011) (0)
- ACI‐24 in adults with Down syndrome: Results of a phase 1b, randomized, placebo‐controlled study (2021) (0)
- P1-030: Chronic nicotine administration does not reduce beta-amyloid levels in a transgenic mouse model for Alzheimer's disease (2008) (0)
- P3-201 Studies on the effect of the apolipoprotein E genotype on the lipid profile in Alzheimer’s disease (2006) (0)
- The lympro® test: A biomarker for Alzheimer’s disease using blood samples from clinically diagnosed Alzheimer’s disease and cognitively intact subjects (2015) (0)
- Are platelet BACE1 levels altered in Alzheimer's disease patients? (2011) (0)
- Plasma biomarkers combined with UPDRS and MoCA for differential assessments of amnestic cognitive impairment (aMCI), Parkinson’s disease (PD+PDD) and dementia with Lewy body (DLB): A pilot study (2022) (0)
- THE LEWY BODY DEMENTIA ASSOCIATION RESEARCH CENTERS OF EXCELLENCE PROGRAM: TOWARD OPTIMIZING CLINICAL CARE AND CLINICAL TRIAL INFRASTRUCTURE (2018) (0)
- THE PRESENCE OF NEURONAL PROTEINS IN HUMAN SUBMANDIBULAR GLAND IN ALZHEIMER’S DISEASE AND NONDEMENTED INDIVIDUALS (2018) (0)
- P2-265 Smoking affects the phenotype of Alzheimer's disease (2004) (0)
- Vascular Health and Risk Management Cerebral blood flow in Alzheimer ’ s disease (2012) (0)
- Research Advances in Diagnostics and Therapeutics in Alzheimer’s Disease (2014) (0)
- Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease (2020) (0)
- Clinical Features Of Patients With Concomitant Parkinson’s Disease And Progressive Supranuclear Palsy Pathology (P5.247) (2014) (0)
- Deep learning-based polygenic risk analysis for Alzheimer’s disease prediction (2023) (0)
- Biochemical characterization of AN1792-immunized Alzheimer's disease individuals (2010) (0)
- RELATIONSHIPS BETWEEN LONGITUDINAL RATES OF LEARNING AND MEMORY DECLINE AND DIFFERENT FORMS OF CEREBROVASCULAR PATHOLOGY IN COGNITIVELY UNIMPAIRED BRAIN DONORS (2019) (0)
- Efficacy and reliability of the visual assessment of 18F-florbetaben PET scans in the detection of beta-amyloid neuritic plaques in the brain (2014) (0)
- BACE1 Inhibitors: Attractive Therapeutics for Alzheimer’s Disease (2014) (0)
- Author Correction: Multimodal hippocampal subfield grading for Alzheimer’s disease classification (2020) (0)
- DEVELOPMENT, APPLICATION, AND RESULTS FROM A CLINICAL INFORMATICS PLATFORM THAT ENABLES A MULTI-MODAL TREATMENT PROTOCOL FOR ALZHEIMER'S DISEASE (AD) (2017) (0)
- Platelet BACE1 levels as a possible biomarker for Alzheimer’s disease (2013) (0)
- Amyloid Imaging with Florbetapir F 18 (18F-AV-45) PET in a subject with Down's Syndrome and Alzheimer's disease at the End of Life (2010) (0)
- Differential diagnosis of neurodegenerative diseases using serum: A new paradigm (2009) (0)
- KIF6 719Arg allele predicts statin responsiveness in amnestic mild cognitive impairment and Alzheimer's disease patients (2012) (0)
- Low Diagnostic Accuracy of a Clinical Diagnosis of Early Parkinson’s Disease: Findings of the Arizona Parkinson’s Disease Consortium (S37.001) (2014) (0)
- An Appraisal of Novel Biomarkers for Evaluating and Monitoring Neurologic Diseases: Editorial Introduction (2016) (0)
- Fielding Questions About Alzheimer's (2008) (0)
- P3-108: Subjective memory complaints in the healthy elderly (2008) (0)
- Author Correction: Multimodal hippocampal subfield grading for Alzheimer’s disease classification (2020) (0)
- Characteristic patterns of inter- and intra-hemispheric metabolic connectivity in patients with stable and progressive mild cognitive impairment and Alzheimer’s disease (2018) (0)
- Pattern Discovery in Brain Imaging Genetics via SCCA Modeling with a Generic Non-convex Penalty (2017) (0)
- Does apolipoprotein E (APO E) genotype influence nicotinic receptor binding in Alzheimer's disease? (2000) (0)
- PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 together distinguish Alzheimer's disease from DLB patients (2011) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Marwan Noel Sabbagh?
Marwan Noel Sabbagh is affiliated with the following schools:
